Get the Stockscreener App
0.00
100.00%
-3.49
Neoleukin Therapeutics Inc stock is currently priced at $0.00, with a 24-hour trading volume of 0.
It has seen a -100.00% decreased in the last 24 hours and a -100.00% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $3.50 pivot point. If it approaches the $3.24 support level, significant changes may occur.
Neoleukin Therapeutics Inc Stock (NLTX) Financials Data
Neoleukin Therapeutics Inc (NLTX) Net Income 2024
NLTX net income (TTM) was -$34.26 million for the quarter ending September 30, 2023, a +42.20% increase year-over-year.
Neoleukin Therapeutics Inc (NLTX) Cash Flow 2024
NLTX recorded a free cash flow (TTM) of -$32.94 million for the quarter ending September 30, 2023, a +31.72% increase year-over-year.
Neoleukin Therapeutics Inc (NLTX) Earnings per Share 2024
NLTX earnings per share (TTM) was -$12.48 for the quarter ending September 30, 2023, a +41.46% growth year-over-year.
Neoleukin Therapeutics Inc Stock (NLTX) Latest News
About Neoleukin Therapeutics Inc
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
COMPANY PROFILE
NameNeoleukin Therapeutics Inc
SectorHealthcare (1201)
IndustryBiotechnology (691)
Web
Phone855 226 6447
Employee77
Twitter
@neoleukin
SEC filings
Latest SEC Filings
Address188 East Blaine Street, Suite 450, Seattle, WA, United States (98102)
1.85%
1.31%
Cap:
|
Volume (24h):